Albiglutide

Drug Profile

Albiglutide

Alternative Names: Albugon; Albumin-GLP-1 fusion protein; Albumin-glucagon-like peptide-1 fusion protein; Eperzan; GLP-1-albumin fusion protein; Glucagon-like peptide-1-albumin fusion protein; GSK 716155; Syncria®; Tanzeum

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Human Genome Sciences
  • Developer GlaxoSmithKline
  • Class Albumins; Antihyperglycaemics; Glucagon-like peptides; Obesity therapies; Recombinant fusion proteins
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Type 1 diabetes mellitus
  • Discontinued Heart failure

Most Recent Events

  • 14 Sep 2017 GlaxoSmithKline withdraws a phase III trial for Type-2 diabetes mellitus (In children, In adolescents) as the asset will be withdrawn from the market prior to study end in USA (SC) (NCT03015519)
  • 24 Jul 2017 GlaxoSmithKline completes a phase III trial for Type-2 diabetes mellitus in Denmark, Hungary, USA, Brazil, Canada, France, Germany, Italy, South Korea, Mexico, Philippines, Poland, South Africa, United Kingdom and Spain (NCT02229227)
  • 23 May 2017 GlaxoSmithKline completes a phase III trial for Type-2 diabetes mellitus (Adjunctive treatment) in USA (SC) (NCT02683746)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top